AzTrials
AzTrials

Kidney Failure, ChronicPHOSPHATENCT03573089

Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

A study testing Liberal phosphate target and Intensive phosphate target in people with Kidney Failure, Chronic and Hyperphosphatemia, run by The University of Queensland at 126 sites in 9 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Kidney Failure, Chronic, Hyperphosphatemia
What is being tested?
Liberal phosphate target and Intensive phosphate target
Could I receive a placebo?
No, everyone receives an active treatment
How many people
3,600 participants
Where
126 sitesin 9 countries
Study dates
10 Dec 2019to 31 Dec 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥45 years, or Age ≥18 years with diabetes,
  • ESKD on haemodialysis or peritoneal dialysis, for at least 3 months,
  • Currently prescribed at least one phosphate-lowering medication at any dose
  • Able to provide informed consent

Who cannot join

  • Elective kidney transplantation scheduled,
  • Concomitant major illness / comorbidity that may result in death in the next 6 months in the view of the treating physician,
  • Participation in an interventional study that is likely to affect serum phosphate concentration.

Trial locations and contacts

126 sites in 9 countries. Contact the study team or a site near you to ask about taking part.

Ron Wald contact

416 867 3703

WaldR@smh.ca

Rona Smith contact

+44 07929642380

rms50@cam.ac.uk

126 sites in 9 countries

United Kingdom46 sites, 46 recruiting

  • NHS Lanarkshire

    Airdrie, North Lanarkshire

    Zoe Cousland, Dr

    Recruiting

  • Wirral University Teaching Hospital NHS Foundation Trust

    Birkenhead, Wirral

    Tom Ledson, Dr

    Recruiting

  • University Hospital Birmingham NHS foundation Trust

    Birmingham

    Kolitha Basnayake, Dr

    Recruiting

  • Bradford Teaching Hospital NHS Foundation Trust

    Bradford, West Yorkshire

    Tarun Bansai, Dr

    Recruiting

  • University Hospitals Sussex NHS Foundation Trust

    Brighton, Sussex

    Farid Ghalli, Dr

    Recruiting

  • West Suffolk Hospital

    Bury St Edmunds, Suffolk

    Nicholas Pritchard, Dr

    Recruiting

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, Cambridgeshire

    Nicholas Pritchard, Dr

    Recruiting

  • East Kent Hospitals University NHS Foundation Trust

    Canterbury, Kent

    Mike Delaney, Dr

    Recruiting

  • Cardiff and Wales University Local Health Board

    Cardiff

    Rhodri Pyart, Dr

    Recruiting

  • North Cumbria Integrated Care NHS Foundation Trust

    Carlisle

    Amer Hayat, Dr

    Recruiting

  • Epsom and St Helier University Hospitals NHS Trust

    Carshalton

    Pauline Swift, Dr

    Recruiting

  • Gloucestershire Hospital NHS Foundation Trust

    Cheltenham

    Madhu Potluri, Dr

    Recruiting

  • Portsmouth Hospitals University NHS Trust

    Cosham

    Katey Flowers, Dr

    Recruiting

  • University Hospitals Coventry & Warwickshire

    Coventry

    Waqar Ayub, Dr

    Recruiting

  • University Hospitals of Derby and Burton

    Derby

    Nitin Kolhe, Dr

    Recruiting

  • Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust

    Doncaster

    Ian Stott, Dr

    Recruiting

  • Dorset County Hospital NHS Foundation Trust

    Dorchester, Dorset

    Joanne Taylor, Dr

    Recruiting

  • The Dudley Group NHS Foundation Trust

    Dudley

    Kunigal Shivakumar, Dr

    Recruiting

  • Royal Devon and Exeter NHS Foundation Trust

    Exeter

    Coralie Bingham, Dr

    Recruiting

  • NHS Greater Glasgow and Clyde

    Glasgow, Kent

    Sokratis Stoumpos, Dr

    Recruiting

  • James Paget University Hospitals NHS Foundation Trust

    Great Yarmouth, Norfolk

    Jean Patrick, Dr

    Recruiting

  • Hull University Teaching Hospital NHS Trust

    Hull

    Sunil Bhandari, Dr

    Recruiting

  • NHS Highland

    Inverness, Scotland

    Stewart Lambie, Dr

    Recruiting

  • Ipswich Hospital (East Suffolk & North Essex Foundation Trust)

    Ipswich

    Richard Smith, Dr

    Recruiting

  • NHS Ayrshire and Arran

    Kilmarnock, Scotland

    Vishal Dey, vishal.dey@nhs.net

    Recruiting

  • University Hospitals Of Leicester NHS Trust

    Leicester

    James Burton, Dr

    Recruiting

  • Royal Liverpool University Hospitals

    Liverpool

    Anirudh Rao, Dr

    Recruiting

  • University Hospital Aintree

    Liverpool

    Christopher Glodsmith, Dr

    Recruiting

  • Guy's and St Thomas' NHS Foundation Trust

    London

    Mike Robson, Dr

    Recruiting

  • King's College Hospital NHS Foundation Trust

    London

    Helen Alston, Dr

    Recruiting

  • St George's University Hospitals NHS Foundation Trust

    London

    Vasantha Muthuppalaniappan, Dr

    Recruiting

  • Manchester University NHS Foundation Trust

    Manchester

    Sandip Mitra, Prof

    Recruiting

  • South Tees Hospitals NHS Foundation Trust

    Middlesbrough, North Yorkshire

    Neil Hoye, Dr

    Recruiting

  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne

    Suren Kanagasundaram, Dr

    Recruiting

  • Nottingham University Hospitals NHS Trust

    Nottingham, Nottinghamshire

    Charlotte Bebb, Dr

    Recruiting

  • University Hospitals Plymouth NHS Trust

    Plymouth, Devon

    Hilary Cramp, Dr

    Recruiting

  • Royal Berkshire NHS Foundation Trust

    Reading

    Bassam Alchi, Dr

    Recruiting

  • Salford Royal NHS Foundation Trust

    Salford

    Maharajan Raman

    Recruiting

  • Sheffield Teaching Hospitals NHS Foundation Trust

    Sheffield, South Yorkshire

    Simon Curran, Dr

    Recruiting

  • Shrewsbury and Telford Hospital NHS Trust

    Shrewsbury, Shropshire

    Kevin Eardley, Dr

    Recruiting

  • Mid and South Essex NHS Foundation Trust

    Southend-on-Sea

    Anthony Yin Keet Chan, Dr

    Recruiting

  • East and North Hertfordshire NHS Trust

    Stevenage, Hertfordshire

    Enric Vilar, Dr

    Recruiting

  • University Hospital of North Midlands NHS Trust

    Stoke-on-Trent, Staffordshire

    Madhavan Menon, Dr

    Recruiting

  • South Tyneside And Sunderland NHS Foundation Trust

    Sunderland, Durham

    Rachel Davison, Dr

    Recruiting

  • The Royal Wolverhampton NHS Trust

    Wolverhampton

    Kay Tan, Dr

    Recruiting

  • York and Scarborough Teaching Hospitals NHS Foundation Trust

    York, North Yorkshire

    Santhanakrishnan Balasubramanian, Dr

    Recruiting

Other trials in United Kingdom

Canada33 sites, 32 recruiting

  • Foothills Hospital/ U of Calgary

    Calgary, Alberta, T2N 4Z6

    Louis Girard, Louis.girard@albertahealthservices.ca

    Recruiting

  • Alberta Health Services

    Edmonton, Alberta

    David Collister

    Recruiting

  • Dalhousie University

    Halifax, Nova Scotia, B3H 4R2

    Karthik Tennankore, KarthikK.tennankore@nshealth.ca

    Recruiting

  • Queen's University

    Kingston, Ontario, K7L 3N6

    Samuel Silver, Samuel.silver@queensu.ca

    Recruiting

  • London Health Sciences Centre

    London, Ontario, N6A 5W9

    Matthew Weir, Matthew.weir@lhsc.on.ca

    Recruiting

  • The Charles Lemoyne Hospital

    Longueuil, Quebec

    Dominic Poirier, Dr

    Recruiting

  • McGill University Health Centre

    Montreal, Quebec, 4A 3J1

    Rita Suri, Rsuri.kidney@gmail.com

    Recruiting

  • Hopital Maisonneuve Rosemont

    Montreal, Quebec, H1T 2M4

    Annie-Claire Nadeau-Fredette, acnadeau-fredette.hmr@ssss.gouv.qc.ca

    Recruiting

  • CHUM

    Montreal, Quebec, H2W 1T8

    William Beaubien, william.beaubien@gmail.com

    Marie-Line Caron, marie-line.caron.chum@ssss.gouv.qc.ca

    Recruiting

  • Jewish General Hospital

    Montreal, Quebec, H3T 1E2

    Daniel Blum, Daniel.blum@mail.mcgill.ca

    Recruiting

  • Sacre Coeur Hospital

    Montreal, Quebec, H4J 1C5

    Remi Goupil, remi.goupil@umontreal.ca

    Recruiting

  • Sunnybrook Health Sciences Centre

    North York, Ontario, M4N 3M5

    Ayodele Odutayo, Dr, ayodele.odutayo@mail.utoronto.ca

    Recruiting

  • Oakville Trafalgar Memorial Hospital

    Oakville, Ontario, L6M 0L8

    Danny Sapir, dsapir@haltonhealthcare.com

    Recruiting

  • Orillia Soldier's Memorial Hospital

    Orillia, Ontario

    Daniel Tascona, Dr

    Recruiting

  • Lakeridge Health

    Oshawa, Ontario, L1G 2B9

    Andrew Steele, asteele@lh.ca

    Recruiting

  • The Ottawa Hospital

    Ottawa, Ontario, K1H 8L6

    Swapnil Hiremath, shiremath@toh.ca

    Recruiting

  • CHU de Quebec Universite Laval

    Québec, Quebec, G1V 4G2

    Fabrice Mac-Way, Fabrice.mac-way@chudequebec.ca

    Recruiting

  • Red Deer Hospital;

    Red Deer

    Sandeep Brar

    Recruiting

  • Prairie Vascular Research Inc

    Regina, Saskatchewan, S4P 0W5

    Bhanu Prasad, Dr, secy.drprasad@sasktel.net

    Recruiting

  • Mackenzie Health

    Richmond Hill, Ontario

    Recruiting

  • Scarborough Hospital Network

    Scarborough Village, Ontario, M1P 2V5

    Paul Tam, pywtam@gmail.com

    Recruiting

  • Centre hospitalier universitaire de Sherbrooke (CHUS)

    Sherbrooke, Quebec, J1H 5N4

    Martin Plaisance

    Recruiting

  • Centre Hospitalier Universitaire de Sherbrooke

    Sherbrooke, Quebec

    Martin Plaisance, Dr

    Recruiting

  • St Michael's Hospital

    Toronto, Ontario, M5B 1W8

    Ron Wald, Dr, 416-867-3703, Ron Wald <Ron.Wald@unityhealth.to>

    Recruiting

  • University Health Network - University of Toronto

    Toronto, Ontario, M5G 1L7

    Charmaine Lok, charmaine.lok@uhn.ca

    Recruiting

  • St. Joseph's Healthcare Hamilton

    Toronto, Ontario, M6R 1B5

    Michael Walsh, Dr, 905-522-1155 ext. 34055, lastwalsh1975@gmail.com

    Recruiting

  • St. Joseph's Healthcare Toronto

    Toronto, Ontario, M6R 1B5

    Joanna Sasal, Joanna.sasal@unityhealth.to

    Recruiting

  • Humber River Hospital

    Toronto

    Gihad Nesrallah

    Recruiting

  • Michael Garron Hospital

    Toronto

    Nausheen Siddiqui

    Recruiting

  • Trillium Health Partners

    Toronto

    Vincent Ki

    Recruiting

  • St. Paul's Hospital

    Vancouver, British Columbia, V6Z 1Y6

    Mercedech Kiaii, mkiaii@providencehealth.bc.ca

    Recruiting

  • Vancouver General Hospital

    Vancouver, British Columbia

    Completed

  • St. Boniface General Hospital

    Winnipeg, Manitoba

    Alex Meraz-Munoz, Dr, amerazmunoz@sbgh.mb.ca

    Recruiting

Other trials in Canada

Australia23 sites

  • Central and Northern Adelaide Renal and Transplant Service

    Adelaide, South Australia, 5000

    Completed

  • Armadale Hospital

    Armadale, Washington, 6112

    Completed

  • Flinders Medical Centre

    Bedford Park, South Australia, 5042

    Completed

  • Sunshine Coast University Hospital

    Birtinya, Queensland, 4575

    Completed

  • Royal Brisbane and Women's Hospital

    Brisbane, Queensland, 4006

    Completed

  • Princess Alexandra Hospital

    Brisbane, Queensland, 4110

    Completed

  • Bundaberg Hospital

    Bundaberg, Queensland, 4670

    Completed

  • Cairns Hospital

    Cairns, Queensland, 4870

    Completed

  • Royal Prince Alfred Hosptial

    Camperdown, New South Wales, 2050

    Completed

  • Austin Health

    Heidelberg, Victoria, 3084

    Completed

  • Fraser Coast Renal Service

    Hervey Bay, Queensland, 4655

    Completed

  • Nepean Hospital

    Kingswood, New South Wales, 2750

    Completed

  • St George Hospital

    Kogarah, New South Wales, 2217

    Completed

  • Mackay Hospital

    Mackay, Queensland, 4740

    Completed

  • Logan Hospital

    Meadowbrook, Queensland, 4131

    Completed

  • Royal Melbourne Hospital

    Melbourne, Victoria, 3050

    Completed

  • St Vincent's Hospital Melbourne

    Melbourne, Victoria, 3065

    Completed

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, 2065

    Completed

  • Gold Coast University Hospital

    Southport, Queensland, 4215

    Completed

  • Townsville University Hospital

    Townsville, Queensland, 4817

    Completed

  • Latrobe Regional Hospital

    Traralgon, Victoria, 3844

    Completed

  • Western Sydney Renal Service

    Westmead, New South Wales, 2145

    Completed

  • Wollongong Hospital

    Wollongong, New South Wales, 2500

    Completed

Other trials in Australia

New Zealand8 sites

  • Auckland City Hospital

    Auckland

    Completed

  • Christchurch Hospital

    Christchurch

    Completed

  • Dunedin Hospital

    Dunedin

    Completed

  • Waikato DHB

    Hamilton

    Completed

  • Hawkes Bay Hospital

    Hastings

    Completed

  • Middlemore Hospital

    Otahuhu

    Completed

  • Waitematā Hospital

    Takapuna

    Completed

  • Northland DHB

    Whangarei

    Completed

Other trials in New Zealand

Brazil6 sites, 6 recruiting

  • Fundacao Felice Rosso - Hospital Felicio Rocho

    Barro Preto

    Lucas Filogonio

    Recruiting

  • Sociedade Hospitalar Angelina Caron

    Campina Grande, Paraíba, 58407-350

    Dalton Bertolin Precoma

    Recruiting

  • BRA Santa Casa de Misericórdia de Ponta Grossa

    Ponta Grossa, Paraná, 84010-200

    Recruiting

  • Hospital de Clinicas Porto Alegre

    Porto Alegre, Rio Grande do Sul

    Fernando Saldanha Thome, Dr, fthome@hcpa.edu.br

    Recruiting

  • Hospital Alemao Oswaldo Cruz

    São Paulo

    Precil Diego M. de M. Neves

    Recruiting

  • Serviço Ubaense de Nefrologia Ltda

    Ubá, Minas Gerais

    Ricardo Furtado, Dr, r.furtado@nefrosun.com.br

    Recruiting

Other trials in Brazil

Israel5 sites, 5 recruiting

  • Hadassah University

    Jerusalem

    Eyal Ophir

    Recruiting

  • Shaare Zedek Medical Centre

    Jerusalem

    Linda Shavit

    Recruiting

  • Meir Hospital

    Kfar Saba

    Keren Cohen

    Recruiting

  • Sheba Hospital

    Ramat Gan

    Pazit Beckerman

    Recruiting

  • Tel Aviv Sourasky Medical Center

    Tel Aviv

    Recruiting

Other trials in Israel

Singapore3 sites, 3 recruiting

  • Khoo Teck Puat Hospital

    Singapore

    Allen Liu Yan Lun, liu.allen.yl@nhghealth.com.sg

    Recruiting

  • Tan Tock Seng Hospital Pte. Ltd.

    Singapore

    Benjamin Khoo Zhi En, benjamin.za.khoo@nhghealth.com.sg

    Recruiting

  • Woodlands Health

    Singapore

    Ibakkanavar Rajiva Guddappa, rajiva.guddappa.ibakkanavar@nhghealth.com.sg

    Recruiting

Other trials in Singapore

France1 site, 1 recruiting

  • AURA Paris Plaisance

    Paris

    Pablo Urena

    Recruiting

Other trials in France

Thailand1 site, 1 recruiting

  • Ramathibodi Hospital

    Bangkok, Khet Ratchathewi, 10400

    Sinee Disthabanchong, Professor, sinee.dis@mahidol.edu

    Recruiting

Other trials in Thailand

About this study

Official title: An Investigator-initiated, International, Multi-centre, Prospective, Randomized, Open-label, Parallel-group, Superiority, and Pragmatic Large Simple Trial (LST) to Determine Whether the Currently Recommended Strategy of Intensive Reduction of Serum Phosphate Concentration Towards the Normal Level Results in Significant Patient-centred Benefits in End-stage Kidney Disease (ESKD) Patients Receiving Dialysis.

During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high levels, lowering blood phosphate levels would reduce death or major events due to heart disease, improve physical health, and be cost-effective.

Read the detailed description

Hyperphosphataemia is highly prevalent in patients with end-stage kidney disease (ESKD) and associated with increased mortality risk. The Clinical Practice Guidelines suggest lowering elevated phosphate levels towards the normal range (level 2C suggestion). However, trial data demonstrating that treatments that lower serum phosphate will improve patient-centred outcomes are lacking.

The primary objective is to test the hypothesis that compared to a liberal serum phosphate concentration target of 2.0 to 2.5 mmol/L, intensive lowering of serum phosphate towards the normal level (≤1.50 mmol/L) with phosphate binders reduces the risk of fatal or non-fatal major cardiovascular events in ESKD patients receiving dialysis. The secondary objectives are to test the hypothesis that intensive lowering of serum phosphate towards the normal level with phosphate binders would improve physical health, fatigue, health-related quality of life, patient satisfaction, and pruritus; and be cost-effective.

In this pragmatic, multinational, randomised controlled large simple trial, a total of 3600 adult ESKD patients receiving dialysis will be randomised either to intensive (≤1.50 mmol/L) or liberalized (2.0-2.5 mmol/L) serum phosphate target. The choice and dose of phosphate binders will be at the treating physician's discretion and local practice to achieve and maintain serum phosphate concentration within the required target range according to randomisation. The primary endpoint is the composite endpoint of cardiovascular death, non-fatal major cardiovascular or peripheral arterial events. The secondary outcome measures will be individual components of the primary composite endpoint, all-cause death, and utility-based quality of life EQ5D-5L.

Being tested
Liberal phosphate target, Intensive phosphate target
Keywords
Renal dialysis, Randomised controlled trial, Bone markers, Cardiovascular risk factors, Phosphate lowering agent, End stage kidney disease, Hyperphosphatemia
Medical subject headings
Kidney Failure, Chronic, Hyperphosphatemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Liberal phosphate targetDrug

    All phosphate-lowering medications in use at baseline will be discontinued. Phosphate-lowering medications will be prescribed only if serum phosphate concentration exceeds 2.50 mmol/L. The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.

  • Intensive phosphate targetDrug

    This will be achieved by prescribing phosphate-lowering medications aimed to intensively lower serum phosphate concentration towards normal level (≤1.50 mmol/L). The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.

Study groups in NCT03573089
Study groupRoleWhat they receive
Liberal phosphate targetActive comparatorLiberal serum phosphate target of 2.0 to 2.5 mmol/L.
Receives: Drug: Liberal phosphate target
Intensive phosphate targetExperimentalIntensive serum phosphate target of ≤1.50 mmol/L.
Receives: Drug: Intensive phosphate target

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to a composite endpoint of cardiovascular death or non-fatal major cardiovascular event

    Time to a composite endpoint of cardiovascular death, non-fatal myocardial infarction or coronary revascularization, stroke, or peripheral arterial event.

    Measured: 5 years

Secondary outcomes (3)

  1. Time to individual components of the primary composite endpoint,

    Measured: 5 years

  2. Time to all-cause death

    Measured: 5 years

  3. Utility-based quality of life EQ5D-5L

    EQ5D-5L will be used to assess patient self-reported quality of life measures.

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jun 2018
  2. Study start10 Dec 2019
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
3,600 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03573089
Sponsor's protocol ID
AKTN 17.02
Acronym
PHOSPHATE
Status last verified
Jun 2026
First submitted
20 May 2018
Last updated
26 Aug 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data that underlie the results reported in the primary publication, after deidentification (text, tables, figures and appendices) will be available for individual participant data meta-analysis.

Publications

  • Edmonston D, Isakova T, Dember LM, Waymyers S, Andersen D, Chan KE, Chakraborty H, Wolf M. Higher versus Lower Phosphate Targets for Patients Undergoing In-Center Hemodialysis: A Randomized Controlled Trial. J Am Soc Nephrol. 2025 Dec 1;36(12):2445-2455. doi: 10.1681/ASN.0000000765. Epub 2025 Jul 10.

    PubMed 40638247

  • Natale P, Green SC, Ruospo M, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.

    PubMed 40576086

  • Fajol A, Faul C. The Pathologic Actions of Phosphate in CKD. Kidney360. 2025 Apr 17;6(6):1040-1049. doi: 10.34067/KID.0000000820.

    PubMed 40241437

  • Fernandez L, Klein J. Vascular Calcification and CKD: Challenges, Emerging Targets, and Future Perspectives. Clin J Am Soc Nephrol. 2025 Nov 1;20(11):1630-1633. doi: 10.2215/CJN.0000000733. Epub 2025 Apr 16. No abstract available.

    PubMed 40238244

  • Edmonston D. Tight Phosphate Control in ESKD Patients Is Warranted: CON. Kidney360. 2024 Dec 13;6(6):895-897. doi: 10.34067/KID.0000000000000401. No abstract available.

    PubMed 39671553

Questions about this trial

What is this clinical trial studying?

A study testing Liberal phosphate target and Intensive phosphate target in people with Kidney Failure, Chronic and Hyperphosphatemia, run by The University of Queensland at 126 sites in 9 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 126 sites in United Kingdom, Canada, Australia, New Zealand, Brazil and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ron Wald (416 867 3703, WaldR@smh.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to a composite endpoint of cardiovascular death or non-fatal major cardiovascular event (time frame: 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03573089, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in